Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Substance Use Disorders (SUD) are often comorbid with psychological trauma, however, the complex interaction between the two is not yet fully understood. Most addiction-specialized professionals do not engage in exploring past traumatic experiences of the patients due to personal, professional, and educational barriers. Therefore, psychological trauma remains highly undetected and its contribution to the development and maintenance of SUD is neglected. This compromises the therapeutic results of most interventions, with relapse rates in SUD still remaining impressively high. EMDR is one of the most effective interventions for Post-Traumatic Stress Disorder (PTSD), and has been applied to other disorders that are often comorbid with trauma, such as psychosis and depression, with promising results. Nevertheless, its application in SUD is still limited. Taken altogether, there is a need to clarify the efficacy of Eye Movement Desensitization and Reprocessing (EMDR) therapy in SUD, as well as the mechanisms of action that mediate its potential therapeutic effects.
The aim of this study is to 1) determine the efficacy of EMDR therapy in patients with SUD comorbid with psychological trauma, as well as whether changes in these clinical variables correspond to changes in salivary cortisol levels- a robust marker of the Hypothalamic-Pituitary-Adrenal (HPA) axis; 2) investigate the mechanisms of action of EMDR therapy, paying special attention to the key role that the cerebellum might play in mediating its therapeutic effects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eye Movement Desensitization and Reprocessing therapy | Experimental | 8 to 10 individual 60-minutes sessions over 2 months. |
|
| Treatment as usual | Active Comparator | Same periodicity as the experimental group and at the same time range. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EMDR | Behavioral | The first session consists of recording the patient's history. In the second session the therapist evaluates the presence of coping mechanisms of the patient and, if necessary, suggests extra coping techniques. The following sessions are devoted to the reprocessing process. During these sessions, a target memory is identified and processed using EMDR. After a total of 8-10 sessions, it is expected that the patient will have achieved physiological reconciliation, relieved distress, and the ability to reformulate negative beliefs. |
| Measure | Description | Time Frame |
|---|---|---|
| time to relapse | Relapse is defined as a return to the addictive behavior, different from a punctual consumption, which is considered as a lapse. This will bee measured by the Time Line Follow Back self-report (TLFB) | 2 months |
| Measure | Description | Time Frame |
|---|---|---|
| changes in functional connectivity | measured by resting-state fMRI | 2 months |
| percentage of conditioned eyeblink responses (CR) | measured by the Eyeblink Conditioning System |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital ClÃnic de Barcelona | Barcelona | Barcelona | 08036 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40792354 | Derived | Sanchez DF, Blithikioti C, Piazza F, Nuno L, Blanco L, Rodriguez-Rey A, Munoz-Moreno E, Balcells-Olivero M, Miquel L. Eye movement desensitisation and reprocessing as a potential treatment for substance use disorders: study protocol. Eur J Psychotraumatol. 2025 Dec;16(1):2531595. doi: 10.1080/20008066.2025.2531595. Epub 2025 Aug 12. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D057169 | Eye Movement Desensitization Reprocessing |
| ID | Term |
|---|---|
| D003887 | Desensitization, Psychologic |
| D001521 | Behavior Therapy |
| D011613 | Psychotherapy |
| D004191 | Behavioral Disciplines and Activities |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| TAU | Behavioral | treatment as usual for substance use disorders |
|
| 2 months |
| CR latency, CR onset, and CR amplitude. | measured by the Eyeblink Conditioning System | 2 months |
| Hair and salivary cortisol levels | Comparison of the Area Under the Curve pre and post treatment | 2 months |
| Craving | Self-report measurement | 2 months 3 months and 5 months |
| Total amount of substance consumed during the previous month | measured by the TLFB | 2 months, 3 months and 5 months |
| Changes in depressive symptomatology | measured by Beck's Depression Inventory (BDI) | 2 months, 3 months and 5 months |
| Changes in anxious symptomatology | measured by The State-Trait Anxiety Inventory (STAI) | 2 months, 3 months and 5 months |
| Changes in posttraumatic symptomatology | measured by Clinician-Administered PTSD Scale (CAPS) | 2 months, 3 months and 5 months |
| Changes in global functioning | measured by Functioning Assessment Short Test (FAST) | 2 months, 3 months and 5 months |